@article{3220684,
    title = "RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response",
    author = "Kallieri, M. and Zervas, E. and Fouka, E. and Porpodis, K. and Mitrova, M.H. and Tzortzaki, E. and Makris, M. and Ntakoula, M. and Papaioannou, A.I. and Lyberopoulos, P. and Dimakou, K. and Koukidou, S. and Ampelioti, S. and Papaporfyriou, A. and Katsoulis, K. and Kipourou, M. and Rovina, N. and Antoniou, K. and Vittorakis, S. and Bakakos, P. and Steiropoulos, P. and Markopoulou, K. and Avarlis, P. and Papanikolaou, Ι.C. and Markatos, M. and Gaki, E. and Samitas, K. and Glynos, K. and Papiris, S.A. and Papakosta, D. and Tzanakis, N. and Gaga, M. and Kostikas, K. and Loukides, S.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2022",
    publisher = "John Wiley and Sons Inc",
    doi = "10.1111/all.15382"
}